此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用数字疗法针对晚年抑郁症冷漠中的网络功能障碍

2026年11月5日 更新者:AdventHealth

The goal of this randomized controlled trial is to evaluate the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypothesize that 4 weeks of a customized digital cognitive training program will lead to changes in brain connectivity, apathy severity, and cognitive control performance.

研究概览

研究类型

介入性

注册 (估计的)

84

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Florida
      • Orlando、Florida、美国、32804
        • 招聘中
        • AdventHealth Neuroscience Institute
        • 首席研究员:
          • Lauren Oberlin, PhD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 60+ years
  2. Diagnosis of unipolar major depressive disorder without psychotic features, as assessed by the Mini International Neuropsychiatric Interview
  3. Montgomery-Åsberg Depression Rating Scale (MADRS) score > or = 16.
  4. Clinically significant apathy, determined by the Clinician-rated Apathy Evaluation Scale (C-AES > or = to 37)
  5. Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 5 weeks.
  6. On a stable dose of other psychotropic medications, deemed by the investigator to be associated with brain networks of interest, for at least 8 weeks.
  7. Capacity to provide written consent for research assessment and treatment
  8. Ability to follow written and verbal instructions (English) as assessed by the PI and/or study staff.
  9. Total score of > 29 on the Telephone Interview for Cognitive Status (TICS)
  10. Eligible to undergo MRI
  11. Access to a computer or tablet with Wifi capabilities
  12. Able to comply with all testing and study requirements and willingness to participate in the full study duration.

Exclusion Criteria:

  1. History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, persistent depressive disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia
  2. Use of cholinesterase inhibitors or psychoactive drugs other than antidepressants or benzodiazepines, including antipsychotics, that in the opinion of the Investigator may confound study data/assessments.
  3. Presence or history of significant neurologic or neurodegenerative disorder (e.g., Alzheimer's disease and other dementias, amnestic Mild Cognitive Impairment, history of stroke, Multiple Sclerosis, Parkinson's disease, epilepsy).
  4. Any other acute medical condition (e.g., cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease; metastatic cancer; or debilitated states or less common medical illnesses) that may influence brain systems of interest or interfere with participation or interpretation of the study results.
  5. Participant is currently considered at risk for attempting suicide by the Investigator, has made a suicide attempt within the past year, or is currently demonstrating active suicidal ideation or self-injurious behavior.
  6. Electroconvulsive therapy within the past 12 months
  7. Recent history (within 6 months prior to screening/baseline) of Substance Use Disorder.
  8. Participant is currently enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is enrolled in psychotherapy, this will not be grounds for exclusion)
  9. Claustrophobia
  10. Color Blindness
  11. Sensory or physical impairment that would preclude cognitive testing or participation in the intervention (e.g., upper limb paralysis) as reported by the participant or observed by the Investigator.
  12. Travelling consecutively for 2+ weeks during the study period to a location that will preclude timely collection of post-treatment MRI data.
  13. Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, cochlear implant, any other metallic biomedical implant contraindicating to MRI.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:有针对性的认知训练干预

In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.

有源比较器:一般认知训练干预

In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Resting State Functional Connectivity among the Salience, Executive Control, and Reward Networks
大体时间:Baseline and Post-treatment (Week 4)

Calculated from resting state fMRI scan. Validation of target engagement.

Baseline and Post-treatment (Week 4)

次要结果测量

结果测量
措施说明
大体时间
Change in Apathy Evaluation Scale (AES) score
大体时间:Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)

The 18-item clinician-rated version of the Apathy Evaluation Scale (AES) will be used to measure apathy severity. Scores range from 18 (no apathy) to 72 (severe apathy).

Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)
Change in Stroop Interference score
大体时间:Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)

Stroop interference will be calculated from the computerized Stroop Task to measure cognitive control.

Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Lauren Oberlin, PhD、AdventHealth

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月19日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2023年5月17日

首先提交符合 QC 标准的

2023年5月17日

首次发布 (实际的)

2023年5月26日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 22-09025304
  • K23MH129882 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data that will be shared includes all of the individual participant data collected during the trial, after deidentification.

IPD 共享时间框架

Beginning 3 months following publication of primary outcomes, ending 5 years following publication of primary outcomes.

IPD 共享访问标准

Data will be made available to researchers who provide a methodologically sound proposal, to achieve the aims in the approved proposal. Proposals should be directed to the study PI, Lauren Oberlin, at lauren.oberlin@adventhealth.com

IPD 共享支持信息类型

  • 研究方案
  • 国际碳纤维联合会
  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅